Profile data is unavailable for this security.
About the company
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
- Revenue in USD (TTM)8.72m
- Net income in USD-20.11m
- Incorporated1990
- Employees75.00
- LocationLineage Cell Therapeutics Inc2173 Salk Avenue, Suite 200CARLSBAD 92008United StatesUSA
- Phone+1 (510) 521-3390
- Fax+1 (510) 521-3389
- Websitehttps://lineagecell.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics Inc | 820.00k | -8.14m | 113.29m | 19.00 | -- | 5.01 | -- | 138.16 | -10.96 | -10.96 | 0.1976 | 2.35 | 0.0128 | -- | 0.6467 | 43,157.89 | -12.46 | -99.64 | -26.07 | -154.42 | 182.20 | 84.69 | -970.49 | -613.58 | -- | -6.69 | 0.00 | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Alto Neuroscience Inc | 0.00 | -57.45m | 115.11m | 88.00 | -- | 0.6977 | -- | -- | -2.42 | -2.42 | 0.00 | 6.12 | 0.00 | -- | -- | 0.00 | -46.93 | -- | -51.10 | -- | -- | -- | -- | -- | -- | -- | 0.0649 | -- | -- | -- | -31.02 | -- | -- | -- |
| TriSalus Life Sciences Inc | 26.89m | -58.65m | 119.30m | 112.00 | -- | -- | -- | 4.44 | -1.68 | -1.68 | 0.8963 | -0.6706 | 0.8812 | 1.23 | 6.75 | 240,098.20 | -181.70 | -- | -265.24 | -- | 87.10 | -- | -206.19 | -- | 2.00 | -26.43 | 17.43 | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Repare Therapeutics Inc | 66.52m | -84.05m | 120.73m | 179.00 | -- | 0.6901 | -- | 1.81 | -2.00 | -2.00 | 1.56 | 4.12 | 0.270 | -- | 3.95 | 371,642.50 | -34.11 | -23.40 | -40.73 | -26.37 | -- | -- | -126.34 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Lineage Cell Therapeutics Inc | 8.72m | -20.11m | 121.12m | 75.00 | -- | 1.83 | -- | 13.89 | -0.1096 | -0.1096 | 0.0474 | 0.3505 | 0.086 | -- | 20.83 | 116,253.30 | -19.77 | -19.53 | -22.80 | -22.59 | 95.00 | 89.13 | -229.91 | -370.88 | -- | -- | 0.0021 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| Ventyx Biosciences Inc | 0.00 | -152.52m | 121.62m | 75.00 | -- | 0.436 | -- | -- | -2.37 | -2.37 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -48.98 | -- | -52.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -30.15m | 122.25m | 5.00 | -- | 1.46 | -- | -- | -0.9117 | -0.9117 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | -55.16 | -- | -58.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.60m | 124.68m | 66.00 | -- | 1.37 | -- | -- | -2.07 | -2.07 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -56.88 | -- | -66.15 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Outlook Therapeutics Inc | 0.00 | -94.05m | 124.90m | 24.00 | -- | -- | -- | -- | -8.12 | -8.12 | 0.00 | -3.57 | 0.00 | -- | -- | 0.00 | -205.48 | -214.69 | -- | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.89 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
| Coherus Biosciences Inc | 304.34m | -450.00k | 126.73m | 235.00 | -- | -- | 26.10 | 0.4164 | -0.0892 | -0.0892 | 2.60 | -0.7636 | 0.5591 | 2.94 | 1.58 | 994,575.20 | -0.0827 | -21.43 | -0.1626 | -29.32 | 44.71 | 79.01 | -0.1479 | -36.56 | 1.09 | -3.92 | 1.50 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Fennec Pharmaceuticals Inc | 49.35m | -1.13m | 127.29m | 36.00 | -- | -- | -- | 2.58 | -0.1004 | -0.1004 | 1.75 | -0.1886 | 1.27 | 2.22 | 5.66 | -- | -2.91 | -73.43 | -3.40 | -84.32 | 93.52 | -- | -2.30 | -383.28 | 7.64 | 0.5978 | 1.21 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Candel Therapeutics Inc | 0.00 | -52.20m | 127.70m | 42.00 | -- | -- | -- | -- | -1.74 | -1.74 | 0.00 | -0.4749 | 0.00 | -- | -- | 0.00 | -145.85 | -- | -227.04 | -- | -- | -- | -- | -- | -- | -30.42 | -- | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Adverum Biotechnologies Inc | 1.00m | -94.11m | 128.35m | 121.00 | -- | 0.8906 | -- | 128.35 | -6.03 | -6.03 | 0.0585 | 6.93 | 0.0046 | -- | -- | 8,264.46 | -43.66 | -36.39 | -50.24 | -39.04 | -- | -- | -9,411.10 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Cardiff Oncology Inc | 689.00k | -43.01m | 129.37m | 31.00 | -- | 2.50 | -- | 187.76 | -0.9493 | -0.9493 | 0.0152 | 1.01 | 0.0091 | -- | 1.69 | 22,225.81 | -56.80 | -31.24 | -66.22 | -33.56 | -- | -- | -6,238.17 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
Data as of Nov 22 2024. Currency figures normalised to Lineage Cell Therapeutics Inc's reporting currency: US Dollar USD
43.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Broadwood Capital, Inc.as of 30 Sep 2024 | 41.67m | 22.07% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 9.21m | 4.88% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 8.28m | 4.38% |
| Defender Capital LLCas of 30 Sep 2024 | 5.00m | 2.65% |
| Logos Global Management LPas of 30 Sep 2024 | 5.00m | 2.65% |
| Raffles Capital Management LLCas of 30 Sep 2024 | 4.51m | 2.39% |
| Geode Capital Management LLCas of 30 Sep 2024 | 3.68m | 1.95% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.61m | 1.38% |
| MAI Capital Management LLCas of 30 Sep 2024 | 1.67m | 0.89% |
| Bank of America, NA (Private Banking)as of 30 Sep 2024 | 1.36m | 0.72% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
